Current and historical daily PE Ratio for SLN (
Silence Therapeutics PLC
) from 2020 to Jun 10 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Silence Therapeutics PLC stock (SLN) PE ratio as of Jun 10 2024 is 0.
More Details
Silence Therapeutics PLC (SLN) PE Ratio (TTM) Chart
Silence Therapeutics PLC (SLN) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 944
- 1
- 2
- 3
- 4
- 5
- 6
- 11
Silence Therapeutics PLC PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-11 | At Loss | 2024-04-05 | At Loss |
2024-06-07 | At Loss | 2024-04-04 | At Loss |
2024-06-06 | At Loss | 2024-04-03 | At Loss |
2024-06-05 | At Loss | 2024-04-02 | At Loss |
2024-06-04 | At Loss | 2024-04-01 | At Loss |
2024-06-03 | At Loss | 2024-03-28 | At Loss |
2024-05-31 | At Loss | 2024-03-27 | At Loss |
2024-05-30 | At Loss | 2024-03-26 | At Loss |
2024-05-29 | At Loss | 2024-03-25 | At Loss |
2024-05-28 | At Loss | 2024-03-22 | At Loss |
2024-05-24 | At Loss | 2024-03-21 | At Loss |
2024-05-23 | At Loss | 2024-03-20 | At Loss |
2024-05-22 | At Loss | 2024-03-19 | At Loss |
2024-05-21 | At Loss | 2024-03-18 | At Loss |
2024-05-20 | At Loss | 2024-03-15 | At Loss |
2024-05-17 | At Loss | 2024-03-14 | At Loss |
2024-05-16 | At Loss | 2024-03-13 | At Loss |
2024-05-15 | At Loss | 2024-03-12 | At Loss |
2024-05-14 | At Loss | 2024-03-11 | At Loss |
2024-05-13 | At Loss | 2024-03-08 | At Loss |
2024-05-10 | At Loss | 2024-03-07 | At Loss |
2024-05-09 | At Loss | 2024-03-06 | At Loss |
2024-05-08 | At Loss | 2024-03-05 | At Loss |
2024-05-07 | At Loss | 2024-03-04 | At Loss |
2024-05-06 | At Loss | 2024-03-01 | At Loss |
2024-05-03 | At Loss | 2024-02-29 | At Loss |
2024-05-02 | At Loss | 2024-02-28 | At Loss |
2024-05-01 | At Loss | 2024-02-27 | At Loss |
2024-04-30 | At Loss | 2024-02-26 | At Loss |
2024-04-29 | At Loss | 2024-02-23 | At Loss |
2024-04-26 | At Loss | 2024-02-22 | At Loss |
2024-04-25 | At Loss | 2024-02-21 | At Loss |
2024-04-24 | At Loss | 2024-02-20 | At Loss |
2024-04-23 | At Loss | 2024-02-16 | At Loss |
2024-04-22 | At Loss | 2024-02-15 | At Loss |
2024-04-19 | At Loss | 2024-02-14 | At Loss |
2024-04-18 | At Loss | 2024-02-13 | At Loss |
2024-04-17 | At Loss | 2024-02-12 | At Loss |
2024-04-16 | At Loss | 2024-02-09 | At Loss |
2024-04-15 | At Loss | 2024-02-08 | At Loss |
2024-04-12 | At Loss | 2024-02-07 | At Loss |
2024-04-11 | At Loss | 2024-02-06 | At Loss |
2024-04-10 | At Loss | 2024-02-05 | At Loss |
2024-04-09 | At Loss | 2024-02-02 | At Loss |
2024-04-08 | At Loss | 2024-02-01 | At Loss |
Silence Therapeutics PLC (SLN) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
![Silence Therapeutics PLC Silence Therapeutics PLC logo](https://static.gurufocus.com/logos/0C00000MTC.png?14)
Silence Therapeutics PLC
ISIN : US82686Q1013
Share Class Description:
SLN: ADRDescription
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.